Home / Stock ratings / Healthcare Stocks / CI
Stock rating · Hospital & Medical Service Plans
The Cigna Group (CI) Stock Rating & Analysis
As of October 6, 2026, MELANY rates The Cigna Group 60 out of 100 (Hold). Its highest factor score is valuation at 87, and its lowest is business quality at 36.
MELANY ratingRated 2026-10-06CI · composite score
About The Cigna Group
Cigna primarily provides pharmacy benefit management and health insurance services. Its PBM and specialty pharmacy operations, substantially expanded by its 2018 merger with Express Scripts, are sold mostly to health insurance plans and employers. Its largest PBM contract is with the Department of Defense, and it recently won a multiyear deal with the major insurer Centene.
Rating as of 2026-10-06 · this is a dated snapshot; the live rating is in the app (Pro, free for 30 days). The price above updates in real time.
Why CI scores 60/100
CI's 8 factor scores run from 36 to 87, and 3 of them sit above its composite of 60. Here is how CI breaks down.
Whether the price looks cheap or expensive against earnings, growth, and peers.
- P/E 11.3x vs sector 22.0x median
- PEG ratio 0.74 (< 1 = undervalued)
- FCF yield 11.0%
Margins, returns on capital, and balance-sheet strength.
Direction and relative strength of the recent share-price trend.
History of beating or missing estimates, and where estimates are heading.
What Wall Street price targets and revisions are signalling.
Near-term events that could move the stock.
Upside weighed against volatility and drawdown risk.
How the current rate and market regime suits this kind of company.
How CI compares
As of October 7, 2026, The Cigna Group is tied for 19th of 20 in Healthcare Stocks, where the average score is 67.
Key risks for CI
- No specific company-level red flags detected, monitor macro regime changes
Sector and theme context
The Cigna Group sits in the Healthcare sector theme, which MELANY currently rates 37/100 for strength. Theme strength feeds CI's momentum and catalyst factors above.
Tracking CI
The Cigna Group rates Hold right now, so MELANY is not flagging a fresh entry. Add CI to a watchlist in the app to follow its rating; an alert the moment it changes is part of Pro, free for 30 days.
How MELANY rates CI
MELANY is a rules-based engine that scores every stock from 0 to 100 across eight weighted factors, then re-scores as new price, earnings, and fundamental data arrive. The Cigna Group's 60/100 reflects mature factor weighting for its profile.
Ratings are algorithmic and change with the data. They are research and education, not personalized investment advice.
Frequently asked questions about CI
Is The Cigna Group (CI) a buy?
As of 2026-10-06, MELANY rated The Cigna Group Hold with a composite score of 60/100. That is a dated snapshot, not the live rating, and it is an algorithmic reading built from eight factors rather than personalized investment advice. Review the factor breakdown above and the disclaimer below before making any decision.
What is The Cigna Group's MELANY score?
The Cigna Group (CI) has a MELANY composite score of 60/100, combining valuation, business quality, price momentum, earnings track record, analyst sentiment, catalyst setup, risk-adjusted profile, macro fit.
How is the CI stock rating calculated?
MELANY scores CI from 0 to 100 across eight weighted factors using live market and fundamental data, then refreshes the rating automatically as new data arrives.
Should I buy The Cigna Group stock?
That decision is yours; Market Eyes Live does not give buy or sell advice. What the data says: MELANY rates The Cigna Group (CI) Hold with a composite of 60/100 as of 2026-10-06. The factor breakdown above shows what is driving that, which is a better basis for a decision than any one-word verdict.
What is the CI stock price forecast?
MELANY does not publish price targets or forecasts for CI. Predicting a future price is exactly the kind of false precision the confidence framework avoids. Instead it scores today's setup, 60/100 across eight factors for The Cigna Group, and re-scores automatically as new price, earnings, and fundamental data arrive.
Is CI stock overvalued or undervalued?
MELANY's valuation factor currently reads 87/100 for The Cigna Group, where a higher score means the price looks more attractive on that measure. Scores in the 70s and above read as attractively priced, the mid range as roughly fair, and low scores as stretched. The factor breakdown above shows what drives CI's read.
What price should I buy CI at?
MELANY is not flagging a fresh entry for CI at its current Hold rating, so there is no entry zone to publish right now. Add CI to a watchlist in the app to follow it; an alert the moment the rating changes is part of Pro, free for 30 days.
What are the risks of buying CI stock?
The top risks MELANY currently flags for The Cigna Group: No specific company-level red flags detected, monitor macro regime changes. The rating on this page already weighs these against the bullish factors; see the risk-adjusted profile score in the breakdown above.
Is The Cigna Group a good long-term investment?
For long-term durability the two factors that matter most are business quality, which MELANY scores 36/100 for The Cigna Group, and earnings track record, at 44/100. The 60/100 composite blends those with six shorter-horizon factors. Durable quality at a fair price is the long-term case to test; this is research, not personalized investment advice.
Will CI stock go up?
Nobody can promise a stock's direction, and Market Eyes Live does not predict prices. The measurable part: MELANY's price momentum factor reads 48/100 for CI right now, and the catalyst setup factor tracks whether near-term events could move it. Both re-score automatically as the data changes.
How current is this CI rating?
The rating on this page is a snapshot of MELANY's read as of 2026-10-06. The price shown updates live, but the score is not recomputed on this page. MELANY re-scores CI continuously as new price, earnings, and fundamental data arrive, and the current rating is in the app (Pro, free for 30 days).
How this rating works
Market Eyes Live
Every rating graded in public, CI included
MELANY scores more than 11,000 U.S. stocks and ETFs, PRISM ranks conviction and APEX writes the plan with one entry zone. Free to start on iOS and the web.